Legal Representation
Attorney
Bridget H. Labutta
USPTO Deadlines
Next Deadline
1465 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-07-18)
Due Date
July 18, 2029
Grace Period Ends
January 18, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Jul 18, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Jul 18, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Jun 15, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Jun 14, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| May 31, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| May 26, 2023 | IUAF | S | USE AMENDMENT FILED |
| May 26, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Feb 7, 2023 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Feb 7, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 7, 2023 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Dec 3, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Dec 2, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Dec 2, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Nov 22, 2022 | EXT5 | S | SOU EXTENSION 5 FILED |
| Nov 22, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 27, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 25, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| May 25, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| May 25, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| May 25, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 25, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| May 25, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Feb 2, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 2, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Feb 2, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jan 13, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jan 13, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jan 13, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jan 5, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jan 5, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Jan 5, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jan 5, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jan 5, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Nov 19, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 17, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Nov 17, 2021 | EXT3 | S | SOU EXTENSION 3 FILED |
| Nov 17, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 27, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| May 25, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| May 25, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| May 25, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 25, 2021 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Feb 25, 2021 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 25, 2021 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Dec 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Nov 27, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Nov 27, 2020 | EXT1 | S | SOU EXTENSION 1 FILED |
| Nov 27, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| May 26, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Mar 31, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Detailed Classifications
Class 042
Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials
First Use Anywhere:
Nov 14, 2007
First Use in Commerce:
Nov 14, 2007
Additional Information
Design Mark
The mark consists of "DICERNA" in stylized blue letters on a white background.
Color Claim
The color(s) blue and white is/are claimed as a feature of the mark.
Classification
International Classes
042
USPTO Documents
Loading USPTO documents...